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Summary 
Recent studies have shown that mucocutaneous leishmaniasis  (MCL), a severe and debilitating 
form of American cutaneous leishmaniasis  (ACL) caused by Leishmania  braziliensis  infection, is 
accompanied by high  circulating levels of tumor necrosis factor (TNF)-oL.  Analysis  of TNF 
polymorphisms in Venezuelan ACL patients and endemic unaffected controls demonstrates a 
high relative risk  (RR)  of 7.5  (P <0.001)  of MCL disease  in homozygotes for allele 2  of a 
polymorphism in intron 2 of the TNF-[3 gene, especially in females (RR  =  9.5; P  <0.001) 
compared with males (RR =  4; P <0.05). A significantly higher frequency (P <0.05) of allele 
2 at the -308-basepair TNF-c~ gene polymorphism was also observed in MCL patients (0.18) 
compared with endemic control subjects (0.069), again associated with a high relative risk of 
disease  (RR  =  3.5; P  <0.05)  even in the heterozygous condition. Because both the TNF-c~ 
and TNF-[3 polymorphisms have previously been linked with functional differences in TNF-oL 
levels, these data suggest that susceptibility to the mucocutaneous form of disease  may be di- 
rectly associated with regulatory polymorphisms affecting TNF-~x production. 
T 
he  reason  some  individuals  infected with  Leishmania 
braziliensis  go on to develop mucocutaneous leishma- 
niasis (MCL), I sometimes months to years after a simple lo- 
calized cutaneous lesion, is not clearly understood.  Clini- 
cally advanced MCL has traditionally been associated with 
strong skin test delayed-type hypersensitivity to leishmanial 
antigens in vivo, and with high IFN-'y/IL-2-producing T 
cell proliferative responses in vitro (1-3). Analysis  of MCL 
lesions  has  demonstrated  mRNA  for  a  mixture  of Thl 
(IFN-% IL-2, TNF-[3) and Th2 (IL-4, IL-5, IL-10) cyto- 
kines  (4,  5),  with  TNF-oL mRNA  also  present.  Recently 
we  observed that active MCL  disease  was  also  associated 
with high circulating levels of TNF-ot (6), which might, as 
has now been demonstrated for cerebral malaria (7), be re- 
lated  to  genetic  regulation  of cytokine  production.  The 
TNF-ot gene itself lies in the class III region of the MHC 
(8). Although previous studies (9) had demonstrated associ- 
ation between class II DR[3 alleles and MCL disease, it was 
possible that these associations had arisen through linkage 
disequilibrium between class II genes and variable genetic 
elements in the class III region known to control TNF-o~ 
IAbbreviations used in this paper: ACL, American cutaneous leishmaniasis; 
df, degree  of  freedom;  LCL, localized  cutaneous  leishmaniasis; MCL, mu- 
cocutaneous leishmaniasis; RR, relative  risk. 
production. Two such polymorphisms have been described, 
at  position  -308  in  the  promoter region  of the  TNF--cx 
gene (10), for which allele 2 is associated with higher con- 
stitutive and inducible levels of TNF-~x (11), and in intron 
2/exon 3 of the TNF-[3 gene (12), with the two polymor- 
phic alleles variably associated with high and low levels of 
TNF-cx secretion by mononuclear cells, depending on the 
population  under investigation  (12-14).  The latter poly- 
morphism involves an NcoI polymorphism in intron 2 and 
is also  always  associated with a substitution at amino acid 
position 26  encoded in  exon 3  of the  TNF-[3 gene  (12). 
Precisely how this polymorphism influences TNF-oL secre- 
tion is not known, but may be caused by linkage disequi- 
librium with other elements within the TNF-~x gene itself. 
To determine whether these polymorphisms at the TNF 
loci influence susceptibility to different forms of American 
cutaneous  leishmaniasis  (ACL),  case/control  analysis  was 
undertaken comparing MCL  patients or localized cutane- 
ous leishmaniasis  (LCL) patients with healthy endemic con- 
trol subjects.  Our  results  demonstrate a  high  relative risk 
(RR =  7.5; P <0.001) of  MCL disease in homozygotes for 
allele 2 (=TNFB*I  [12-14]) of the intron 2/exon 3 poly- 
morphism in the TNF-[3 gene, especially in females (RR = 
9.5; P <0.001) compared with males (RR =  4; P <0.05). 
A significantly higher frequency (P <0.05) of allele 2 at the 
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MCL  patients  (0.18)  compared  with  endemic  controls 
(0.069),  again associated with  a  high relative risk  (RR  = 
3.5;  P  <0.05)  of disease even in the heterozygous condi- 
tion. These results suggest that susceptibility to the muco- 
cutaneous  form  of disease may be directly associated with 
regulatory polymorphisms affecting TNF-ot production. 
Materials and Methods 
Study  Design.  Genomic  DNA  was  extracted  from  EBV- 
transformed cell lines prepared from 49 ACL patients (age range 
11-48 yr) and 43 control subjects (age range =  13-45 yr). As be- 
fore (1-3), patients were classified on the basis of clinical, parasi- 
tological, and histopathological criteria (15) as LCL (n  =  24;  16 
males, 8 females; mean age =  26.7 +  8.6 yr) or MCL (n =  25;  14 
males,  11 females;  mean age =  30.4  -+ 10.6 yr). The sample was 
drawn from patients routinely attending clinic at the Instituto de 
Biomedicina in Caracas, Venezuela. Patients travel to the clinic 
from  periurban  and  rural  regions  surrounding  Caracas,  mostly 
from Miranda state. All MCL and the majority of LCL disease in 
this region is caused by L. braziliensis (15). The higher proportion 
of male to female patients presenting with L. braziliensis infection 
in Venezuela is thought to be related to higher occupational ex- 
posure to the vector sandfly. There are no longitudinal data avail- 
able on the relative proportions of males to females progressing to 
MCL disease. To test for association between TNF or HLA-DR 
and disease,  ACL patients (MCL alone, LCL alone, and pooled) 
were  compared  with  43  endemic  volunteers  selected  as  age- 
matched (mean age 24.9  ___  8.8 yr; 12 males, 31  females)  control 
subjects from a recent vaccine trial carried out in Miranda state, 
Venezuela (16, 17). A larger set of 64 individuals (18 males, mean 
age =  18.9  +  6.5 yr; 46 females,  mean age 22.5  +  8.2 yr) from 
the vaccine trial were used in testing for linkage disequilibrium 
between the  TNF  genes  and HLA-DR[3.  Volunteers were se- 
lected into the trial on the basis of a double skin test-negative re- 
sponse to mycobacterial purified protein derivative and to leish- 
manial  antigen.  They  had  no  scars  from  previous  leishmanial 
lesions  or  Bacille  Calmette-Gu~rin  vaccination,  and  no  other 
clinical history ofleishmaniasis. 
Typing of HLA-DR~,  TNF-a and  TNF-~8 Genes.  DRy3 typ- 
ing (18) was carried out by Southern blot analysis of RFLPs. This 
method does not distinguish between DR3  and DRw6,  or be- 
tween  DR7  and  DRw9.  DR15  and  DR16  subtypes  of DR2 
were pooled for analysis. For PCR  amplification of TNF-ot and 
TNF-13 regions, 1 Ixg of DNA was added to 40  I~1 of reaction 
mixture containing 100 ng of each primer (TNF-Ix: 5' AGGCA- 
ATAGGTTITGAGGGCCAT 3', 5' TCCTCCCTGCTCCGAT- 
TCCG  3';  TNF-I3:  5'  CCGTGCTTCGTGCTTTGGACTA 
3',  5'  AGAGCTGGTGGGACATGTCTG  3'),  0.25  mM  of 
each dNTP,  1.5  mM  MgC12, and  1 U  Taq  polymerase (Cetus 
Corp.,  Berkeley, CA).  Cycling conditions for TNF-a  were  as 
follows: 1 cycle of 94~  for 3 rain, 60~  for 1 rain, 72~  for 1 
rain; 35  cycles of 94~  for  1 min,  60~  for  1 min,  72~  for  1 
rain; 1 cycle of 94~  for 1 rain, 60~  for 1 rain, 72~  for 5 rain. 
Cycling conditions for TNF-18 were as follows: 95~  for 6 rain, 
35 cycles of 94~  for 1 min, 65~  for 1 rain, and 72~  for 1 rain. 
Products  of 107  and  740  bp  were  generated  for  TNF-oL  and 
TNF-[3, respectively. For TNF-ot, primers were designed to in- 
corporate a polymorphic site at a position -308 bp of the TNF-ot 
gene into an NcoI restriction site. Restriction digests generated 
products of 87 and 20 bp for allele 1 and 107 bp for allele 2. The 
740-bp fragment amplified across  intron 2  of the  TNF-13  gene 
also incorporates a polymorphic NcoI site, which generates frag- 
ments of 740 bp for allele 1  (=TNFB*2  or the  10-kb allele of 
previous  workers  [12-14]),  and  555  plus  185  bp  for  allele  2 
(=TNFB*I or the 5.5-kb allele [12-14]). 
Statistical Analyses.  The  X  2  test  with  Yates  correction  or 
Fisher's exact test were used to test for significant associations be- 
tween disease phenotype (LCL, MCL, or pooled ACL against en- 
demic controls) and HLA-DR[3, TNF-ot, or TNF-I3 genotypes 
or alleles. Relative risks associated with a particular allele (e.g., al- 
lele 2) were calculated (19) using a ￿  distribution: RR  =  nl.n4/ 
n2.n3, where n 1 is the proportion of patients carrying allele 2, n2 is 
the number of controls with allele 2, and n  3 and n  4 are the corre- 
sponding proportions of individuals in patient and control groups 
not  carrying  allele  2.  The  test  statistic  is  calculated as  (l/V) 
(logeR.R) 2, where  V =  1/n l +  1/n  2 +  1/n  3 +  1/n  4. The value is 
compared with a ￿  distribution with one degree of freedom and 
must  be  >3.84  to  attain  statistical significance (P <0.05). 
To  test for linkage disequilibrium between DtM3 and the TNF 
loci, the distribution of DRI3 alleles among individuals homozy- 
gous at the TNF-ot or TNF-[3 genes was compared in all ACL 
patients plus control subjects (using the larger vaccine volunteer 
group). Associations with disease  type were also  analyzed using 
computer-generated haplotype frequencies obtained by an itera- 
tive procedure based on the gene counting technique (20).  This 
computer-assisted analysis was carried out using the linkage utility 
program ASSOCIATE on-line to the HGMP Resource Centre 
(Cambridge, UK). 
Results and Discussion 
Association between  DR~  and Disease.  Table  1 shows al- 
lele frequencies for DRI3 in the three patient groups (ACL 
and the two subgroups, LCL and MCL)  and age-matched 
controls. As with previous studies (9), DR2  showed a sig- 
nificantly reduced frequency in MCL  patients  (0.04),  and 
in ACL patients overall (0.09), compared with control sub- 
jects (0.18). DR.7/DR.w9,  which had a very low frequency 
(0.01)  in  the  control  population,  showed  a  significantly 
higher frequency in LCL patients  (0.11),  and  in ACL pa- 
tients overall (0.08),  compared with control subjects. Both 
effects were  sufficiently strong  to  cause  significant differ- 
ences when the total ACL group was compared with con- 
trol subjects, even though LCL patients did not themselves 
show a significant decrease in DR2,  and MCL patients did 
not show a significant increase in DR7/DRwg. 
Association  between  Disease and  Polymorphisms at the  TNF 
Loci.  Table  1  also  shows  allele  frequencies  for  the  two 
TNF genes in the three patient groups and control subjects. 
The distribution ofgenotypes for the two TNF loci among 
control  and  patient groups  is  shown  in  Table  2.  For the 
TNF-ot  promoter  region  polymorphism,  where  the  rarer 
allele 2  had  previously been  shown  to be  associated with 
increased risk of cerebral malaria in Gambian children (7), 
only two homozygotes were observed in the total popula- 
tion sample, within the LCL group. Nevertheless, the gene 
frequency for allele 2 was significantly (P <0.05)  higher in 
MCL patients (P <0.18)  compared with control subjects (P 
<0.07).  The  overall gene  frequency  for  this  allele in  pa- 
tients  plus  control  subjects  was  0.12,  similar  to  the  fie- 
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Patients Stratified by Disease Phenotypes LCL and MCL 
Controls (n =  43)  ACL (n =  49)  LCL (n =  24)  MCL (n =  25) 
Locus/allele  f  f  P  f  P  f  P 
DR1  0.08  0.06  NS  0.07  NS  0.04  NS 
DR.2 (15/16)  0.18  0.09  <0.05  0.13  NS  0.04  <0.05 
DR.3/DRw6  0.26  0.23  NS  0.16  NS  0.31  NS 
DR.4  0.20  0.24  NS  0.22  NS  0.27  NS 
DR5  0.17  0.26  NS  0.27  NS  0.26  NS 
DR7/DRw9  0.01  0.08  <0.05  0.11  <0.02  0.04  NS 
DRw8  0.05  0.04  NS  0.04  NS  0.04  NS 
DR10  0.01  0  NS  0  NS  0  NS 
DRw8  0.04  0  NS  0  NS  0  NS 
TNF-od  0.93  0.84  0.85  0.82 
TNF-a2  0.07  0.16  NS  0.15  NS  0.18  <0.05 
TNF-131  0.69  0.51  0.60  0.42 
TNF-f32  0.31  0.49  <0.025  0.40  NS  0.58  <0.01 
Fisher's exact test was used to determine whether significant differences (P values) in gene frequencies were observed when each patient group (ACL 
or LCL and MCL subgroups) were compared with endemic control subjects, n, number of individuals in each group; 2n, number of chromosomes 
scored to determine allele frequencies. Similar results were obtained when the larger control group was compared with the patient groups, i.e. with- 
out precise age matching. 
quency of 0.16 maintained in the Gambian population de- 
spite  the  increased risk  of death  or  neurological sequelae 
from cerebral malaria. The relative risk of MCL disease as- 
sociated with allele 2,  even in the  heterozygous  condi- 
tion,  was  3.5  (P <0.05).  For the TNF-[3 polymorphism, 
a high relative risk (RR  =  7.5;  P  <0.001)  of MCL disease 
was observed in individuals homozygous for allele 2. Strati- 
fication by sex revealed a higher relative risk in homozygous 
females ~  =  9.5;  P  <0.001)  compared with  homozy- 
gous  males  (P,R  =  4.0;  P  <0.05).  The  relative  risk  of 
MCL  associated with  allele 2  in  the  heterozygous or ho- 
mozygous  condition was  3.2  (P <0.05):  2.9  (P <0.05)  in 
females and 4.0  (P <0.001)  in males; thus,  for females the 
risk  is  higher  when  allele 2  is  homozygous,  whereas  for 
males an equivalent risk occurs when one or two copies of 
allele 2 are present. 
Evidence That TNF-a Is the Functionally Important Locus in 
Determining  MCL  Disease.  The  observation  that  active 
cases of MCL have high circulating TNF-o~ levels (6) sug- 
gests that  the  functional basis of the  associations between 
disease phenotype and HLA class II and class III genes ob- 
served  here  may  result  from  linkage  disequilibrium with 
regulatory elements influencing TNF-oL transcription. The 
-308-bp  polymorphism  at  the  TNF-oL  gene  has  already 
been  shown  to  be  a  functionally important promoter  re- 
gion  element  influencing TNF-ol transcription  (11).  This 
polymorphism might  therefore  be  directly responsible for 
MCL disease in individuals bearing at least one copy of al- 
lele 2. 
Polymorphism at the TNF-[3 locus was also significantly 
associated with  MCL  disease.  Although  significant  (P  = 
0.004)  allelic  association  between  TNF-a  and  TNF-[3 
genes  was  demonstrated  in  the  total  population  sample, 
case/control ratios for haplotype frequencies in ACL, LCL, 
Table  2.  Distrubution  of TNF-a and TNF-~ Genotypes in 
Control Subjects, Age-matched A CL Patients, and Age-matched 
ACL Patients Stratified by Disease Phenotypes LCL and MCL 
Locus/genotype/  Controls  ACL  LCL  MCL 
haplotype  (n =  43)  (n =  49)  (n =  24)  (n =  25) 
TNF-a* 
1/1  37  35  19  16 
1/2  6  12  3  9 
2/2  0  2  2  0 
TNF-~* 
1/1  19  15  10  5 
1/2  21  20  9  11 
2/2  3  14  5  9 
*X2/4) =  11.41, P <0.05 overall. 
:~X2(4)  =  10.45, P <0.05 overall; X2(2)  =  10.25, P <0.01 for control sub- 
jects versus MCL;  X2(2) =  7.25,  P  <0.05  for control subjects versus 
ACL. 
n, number of individuals in each group. 
The subscripted (2) and (4) represent degrees of freedom (dr). 
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Disease Phenotypes LCL and MCL 
Haplotype frequencies 
Control subjects  ACL  LCL  MCL 
Haplotype  (2n =  128)  (2n  =  92)  (2n =  46)  (2n  =  46) 
TNF-{xl .TNF-[B1  0.69  0.42  (0.6)  0.49  (0.7)  {}.35  (0.5) 
TNF-u 1 .TNF-IB2  0.24  0.42  (1.7)  {/.36  (1.5)  0.48  (1.9) 
TNF-{x2.TNF-[31  0.01  0.06  (5.9)  0.07  (7.4)  0.04  (4.1) 
TNF-o~2.TNF-[32  0.06  0.10  (1.7)  0.08  (1.3)  0.13  (2.2) 
X2(3)  17.23"  9.07*  16.34* 
*P <0.{)01, *P <0.005. 
X2(3) tests for significant differences in the distribution ofTNF-ot. TNF-13 haplotypes between  controls and each of the three patient groups. Case/ 
control ratios for haplotype frequencies are shown in parentheses. 2n, number of chromosomes scored to determine haplotype frequencies. 
The subscripted (3) represents dE 
and MCL patients  compared with  control subjects  suggest 
an  equivalent  risk  (case-control  ratios  for TNF-otl.TNF- 
[32, TNF-{x2.  TNF-[31,  or TNF-ot2.TNF-[32  all >1.0)  in 
individuals  bearing either TNF-o~ allele 2  or TNF-[3 allele 
2  (Table 3). Hence,  there is a significant negative risk asso- 
ciated with  the haplotype TNF-{x1.TNF-[31  (case/control 
ratios  <1.0)  for  both  LCL  (RR  =  0.45;  P  <0.05)  and 
MCL (RR  =  0.24;  P  <0.01)  groups. Using the computer- 
generated  haplotype frequencies,  a significant  difference in 
the  distribution  of haplotypes  was  observed  (Table  3)  in 
ACL (￿  =  17.23;  P  <0.001),  LCL (X  2 =  9.07;  P  <0.05), 
or MCL  (X  2  =  16.34;  P  <0.001)  compared with  control 
subjects.  The  significance  levels  reflect  the  intermediate 
magnitude  of serum  TNF-{x  levels  observed  in  LCL  pa- 
tients  (68  -  34  pg/ml)  compared with  MCL patients  (94 
+_  13 pg/ml)  and control subjects  (12  +  3 pg/ml)  (6). Be- 
cause  MCL  patients  arise  as  a  subset  of initially  LCL  pa- 
tients, it is likely that the LCL patient group xvill contain a sub- 
set of high TNF-{x producers predisposed to MCL disease. 
The fact that TNF-[3 allele 2 is independently  associated 
with  MCL  disease  suggests  that  it  is in  linkage  disequilib- 
rium  with  other  regulatory  elements  for TNF-0~  produc- 
tion.  In  previous  studies,  the  two  alleles  of the  TNF-13 
gene have been shown to be in linkage disequilibrium with 
different  DRI3  alleles,  and  both  DR{~  and  TNF-~  have 
been shown to be associated with functional  differences in 
LPS-induced  TNF-cl  secretion  by mononuclear  cells  (12, 
14,  21,  22),  or  with  TNF-0~  secretion  by  nonstimulated 
EBV cell lines  (13).  Two of these studies  (21,  22)  demon- 
strated that mononuclear  cells from DR2-positive  individ- 
uals  exhibit  low  TNF-o~  production  in  response  to  LPS, 
whereas  DR3-  and  DR4-positive  individuals  show  high 
levels of TNF-o~ production.  In our total study population 
(Table  4),  DR2  was in linkage  disequilibrium  (P =  0.03) 
with  the  higher  frequency  allele  1  of the  TNF-13  gene 
(=TNFB*2  [12-14]),  and both DR2  and the TNF-~31  al- 
lele  were  significantly  reduced  in  the  MCL  patient  group 
(Table 1). Conversely, DR3 and DR4 were each associated 
(P <0.05)  with allele 2 of the TNF-[3 gene (TNFB*I  [12- 
14])  (Table 4), which was significantly increased in individ- 
uals with MCL disease (Table  1). Although DR3 and DR4 
were  not  individually  associated with  MCL disease  (Table 
1),  haplotype  frequencies  (Table  5)  for  DR3.TNF-I~2 
(0.23  in MCL patients compared with 0.08 in control sub- 
jects)  and DR4.TNF-O2  (0.18  in MCL patients compared 
with 0.09  in control  subjects)  made up  a large component 
of the overall TNF-[32 disease association.  For DR3,  case/ 
control  ratios  of >1.0  (Table  5)  for  DR3.TNF-132  and 
non-DR3.TNF432  indicate that the risk of MCL lies with 
TNF-~2  independently  of DR3.  For  DR4,  case/control 
ratios  >1.0  were associated with  either DR4  or TNF-[32, 
suggesting that susceptibility to MCL is associated with  an 
element  in  linkage  disequilibrium  with  both.  In  previous 
studies,  the  particular  allele at the  TNF-[8  gene  associated 
with  TNF-ot  secretion  varies according  to  the  population 
Table 4.  Tests  for Linkage Disequilibrium between DRy} and 
TNF-~8 Allele.; in the Total Population Sample 
TNF-I3 
homozygotes 
DRIB  1/1  2/2  X  2  Pl  P2 
DR2  18  3  4.11  <0.05  0.03 
Non-DR2  66  39 
DR3  17  16  4.29  <{).05  0.07 
NON-DR3  65  26 
DR4  10  10  2.97  0.07  0.05 
NON-DR4  74  32 
Associations (X  2, Pl) between DR[3 and TNF-13 alleles are calculated 
using only individuals homozygous at the TNF-13 locus. These associa- 
tions were confirmed (P2) using the computer-generated  haplotype fre- 
quencies. 
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Phenotypes LCL and MCL 
Haplotype frequencies 
Control subjects  ACL  LCL  MCL 
Haplotype  (2n =  128)  (2n =  92)  (2n =  46)  (2n =  46) 
DR2.TNF-131  0.15  0.06  (0.4)  0.10  (0.6)  0.02  (0.1) 
DR2.TNF-IB2  0.03  0.03  (l .0)  0.04  (1.2)  0.02  (0.8) 
Non-Dr2.TNF-[31  0.54  0.42  (0.8)  0.47  (0.9)  0.37  (0.7) 
NON-Dr2.TNF-[32  0.28  0.49  (1.8)  0.40  (1.5)  0.59  (2.1) 
X2{3~  12.63*  2.85 w  16.07' 
Dr3.;FNF-[31  0.15  0.07  (0.5)  0.06  (0.4)  0.07  (0.5) 
DR3.TNF-[32  0.08  0.18  (2.2)  0.13  (1.6)  0.23  (2.8) 
Non-DR3.TNF-[31  0.55  0.41  (0.8)  0.50  (0.9)  0.32  (0.6) 
Non-DR3.TNF-[32  0.22  0.34  (1.5)  0.30  (1.4)  0.38  (1.7) 
X2(3)  12.06"  3.88 ~  14.31" 
DR4.TNF-[31  0.10  0.12  (1.3)  0.10  (1.1)  0.16  (1.6) 
DR4.TNF-[32  0.09  0.16  (1.7)  0.11  (1.3)  0.18  (2.0) 
Non-DR4.TNF-131  0.60  0.37  (0.6)  0.46  (0.8)  0.25  (0.4) 
Non-DR4.TNF-[32  0.21  0.36  (1.7)  0.32  (l .5)  0.41  (1.9) 
￿  )  11.91"  2.95 w  16.40' 
*P <0.01, *P <0.001;  w  NS. 
X2(3) test for significant differences in the distribution ofDR.TNF-[3 haplotypes between controls and each of the three patient groups. Case/control 
ratios for haplotype frequencies are shown in parentheses. 2n, number of chromosomes scored to determine haplotype frequencies. 
The subscripted (3) represents dr. The boldface numbers represent the differences between MCL cases and control subjects, as discussed in the text. 
under investigation.  Hence,  Messer  et  al.  (12)  and  Pociot 
and coworkers (14)  found TNFB*2,  the equivalent of our 
TNF-[31  allele,  to be associated with  high TNF-0t  release 
in  individuals  with  the  DR4.TNFB*2  haplotype.  Con- 
versely, Abraham and co-workers (13)  found high TNF-ot 
secretion to be associated with TNFB*I, the equivalent of 
our  TNF-f32  allele,  in  individuals  bearing  the  DR3. 
TNFB*I  haplotype.  Although  further  analysis  is  required 
to provide the functional link between regulatory elements 
and TNF-or levels in Venezuelan MCL patients,  our MHC 
associations appear to concur with  the low TNF-~  secre- 
tion associated with DR2 and the TNFB*2 allele, and high 
TNF-0~  secretion  associated  with  DR3.TNFB*I  and 
DR4.TNFB*I  haplotypes. 
Overall, the results of this study indicate a strong relative 
risk of MCL disease associated with particular alleles  at the 
TNF-ot  and  TNF-[3  genes  in  the  class  III region  of the 
MHC.  Together with  the  recent  observation  (7)  that  in- 
creased risk of cerebral  malaria  is similarly associated with 
functional  polymorphisms  influencing  TNF-ot  secretion, 
our results highlight the possible impact that polymorphism 
at this locus might have in determining susceptiblity to se- 
vere  clinical  forms  of infectious  disease,  as  well  as  in  au- 
toimmune  disease  (12,  14,  21-24).  Further  analysis of the 
TNF-0L/TNF-[3  gene  region  is  required  to  identify  all 
polymorphisms associated with disease,  to test their role in 
TNF-o~ regulation, and to determine the positive balancing 
selection  that  must  operate  to  maintain  these  apparently 
deleterious alleles  in the population. 
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